SURMOUNT-MMO: tirzepatide for morbid obesity — trial update

Great question. Here's the simplified version:

LDL-C measures the amount of cholesterol carried by LDL particles. But LDL particles vary in size. Small, dense LDL particles carry less cholesterol each but are more atherogenic (they penetrate the arterial wall more easily and are more prone to oxidation).

ApoB counts the number of atherogenic particles. Each LDL, VLDL, IDL, and Lp(a) particle has exactly one ApoB molecule. So ApoB tells you how many "bullets" are hitting your arterial wall, regardless of how much cholesterol each bullet carries.

In patients with metabolic syndrome and high triglycerides (like many GLP-1 users at baseline), LDL-C often underestimates risk because they have many small, cholesterol-depleted LDL particles. Their LDL-C might read 110 mg/dL (seemingly okay), but their ApoB could be 140 mg/dL (high risk) because they have far more particles than someone with the same LDL-C but large, buoyant particles.

"ApoB is a more accurate predictor of cardiovascular risk than LDL-C, particularly in patients with metabolic syndrome, diabetes, or hypertriglyceridemia."

Ask your doctor to add ApoB to your next lipid panel. It's a simple blood test covered by most insurance.

To bring this back to the clinical bottom line: the current European guidelines (ESC/EAS 2019) already recommend ApoB as a secondary lipid target alongside LDL-C. The AHA/ACC have increasingly endorsed its utility.

Target ApoB levels based on risk:

• Low risk: <130 mg/dL
• Moderate risk: <100 mg/dL
• High risk (ASCVD, T2DM): <80 mg/dL
• Very high risk (recurrent events): <65 mg/dL

The earlier post showing statin + tirzepatide producing an ApoB of 62 mg/dL is remarkable — that patient has achieved a "very high risk" target with just a moderate-intensity statin plus tirzepatide. Traditionally, hitting that level required high-intensity statin + ezetimibe or a PCSK9 inhibitor.

Important thread. ApoB is indeed becoming the gold standard for atherogenic lipid assessment, and the interplay between GLP-1/GIP therapy and traditional lipid management is an evolving field. Please note that lipid targets and treatment decisions should be individualized — this discussion is educational, not prescriptive.